Andere talen Brii Biosciences Limited

Aandelen

2137

KYG1645A1094

Vertraagde tijd Hong Kong S.E. Andere beurzen 08:16:54 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,98 ^HKD	+6,52%		+1,03%	-57,02%

25/03	Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024
22/03	Brii Biosciences Limited rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results	25/03
Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179	05/03
VBI Vaccines Sells Rights to Hepatitis B Vaccine to Brii Biosciences	14/02
Brii Biosciences to Buy Rights to Hepatitis B Vaccine from VBI	14/02
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies	14/02
Brii Biosciences Hires Chief Scientific Officer	04/01
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer	03/01
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer	03/01
Brii Biosciences Presents Hepatitis B Treatment Data at US Liver Disease Conference	14/11
PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023	14/11
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 in Combination with PEG-IFN for the Treatment of Chronic Hepatitis B	07-09-23
Brii Biosciences’ Study Into Therapeutic Vaccine for Chronic Hepatitis B Patients Shows Safety, Tolerability	06-09-23
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B	06-09-23
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating Brii-179 (Vbi-2601) in Combination with Peg-Ifn for the Treatment of Chronic Hepatitis B	06-09-23
Brii Biosciences Limited Announces Data from Interim Analysis of A Randomized, Placebo-Controlled and Double-Blinded Phase 2 Study of Brii-179	06-09-23
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results	22-08-23
Brii Biosciences Limited Reports Earnings Results for the Half Year Ended June 30, 2023	22-08-23
Shionogi Inc. completed the acquisition of Qpex Biopharma, Inc. from Brii Biosciences Limited and Others.	31-07-23
Brii Biosciences Collaborates with VBI Vaccines for Hepatitis B Project	06-07-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Brii Biosciences Limited

Aandelen

2137

KYG1645A1094

Andere talen

Filters